|
Characteristic
|
Luminal A (n = 119)
|
Luminal B Ki67+ (n = 52)
|
Luminal B HER2 + (22)
|
HER2 overexpression (16)
|
TNBC (46)
|
Statistics
|
P
|
|---|
|
Age (years)
|
51.67 ± 10.10
|
50.88 ± 8.16
|
55.41 ± 8.98
|
52.13 ± 6.49
|
51.91 ± 10.90
|
0.896
|
0.467
|
|
Menopause
| | | | | |
2.378
|
0.667
|
|
Postmenopausal
|
56
|
24
|
14
|
7
|
22
| | |
|
Premenopausal
|
63
|
28
|
8
|
9
|
24
| | |
|
Family history
| | | | | |
2.075
|
0.722
|
|
No
|
109
|
49
|
21
|
16
|
42
| | |
|
Yes
|
10
|
3
|
1
|
0
|
4
| | |
|
Diameter
|
2.15 ± 0.98
|
2.32 ± 0.94
|
2.43 ± 1.07
|
3.09 ± 1.49
|
2.50 ± 1.18
|
3.292
|
0.012
|
|
Quadrant
| | | | | |
16.851
|
0.395
|
|
Areolar
|
3
|
1
|
0
|
0
|
1
| | |
|
Inner upper
|
28
|
8
|
0
|
2
|
7
| | |
|
Inner lower
|
14
|
5
|
1
|
2
|
3
| | |
|
Outer lower
|
21
|
11
|
3
|
2
|
6
| | |
|
Outer upper
|
53
|
27
|
18
|
10
|
29
| | |
|
Enhancement patterns
| | | | | |
59.901
|
0.000
|
|
Homogeneous
|
40(33.6%)
|
18(34.6%)
|
7(31.8%)
|
5(31.3%)
|
12(26.1%)
| | |
|
Heterogeneous
|
71(59.7%)
|
29(55.8%)
|
8(36.4%)
|
3(18.8%)
|
10(21.7%)
| | |
|
Peripherals
|
8(6.7%)
|
5(9.6%)
|
7(31.8%)
|
8(50.0%)
|
24(52.2%)
| | |
|
Difference of MVD (Edge - Center)
|
3.12 ± 6.26
|
3.18 ± 7.95
|
7.61 ± 8.53
|
7.98 ± 8.97
|
10.23 ± 8.72
|
9.543
|
0.000
|
|
Grade of DMVD
| | | | | |
42.300
|
0.000
|
|
Uniform distribution
|
102(85.7%)
|
44(84.6%)
|
14(63.6%)
|
6(37.5%)
|
21(45.7%)
| | |
|
Uneven distribution
|
17(14.3%)
|
8(15.4%)
|
8(36.4%)
|
10(62.5%)
|
25(54.3%)
| | |
|
Histological grade
| | | | | |
30.927
|
0.000
|
|
I
|
37(31.1%)
|
16(30.8%)
|
0(0%)
|
1(6.3%)
|
9(19.6%)
| | |
|
II
|
77(64.7%)
|
29(55.8%)
|
16(72.7%)
|
10(62.5%)
|
34(73.9%)
| | |
|
III
|
5(4.2%)
|
7(13.5%)
|
6(27.3%)
|
5(31.3%)
|
3(6.5%)
| | |
|
Cancer thrombosis
| | | | | |
7.806
|
0.099
|
|
Negative
|
89
|
41
|
11
|
10
|
34
| | |
|
Positive
|
30
|
11
|
11
|
6
|
12
| | |
|
Nodal metastasis
| | | | | |
6.825
|
0.145
|
|
Negative
|
60
|
24
|
8
|
3
|
23
| | |
|
Positive
|
59
|
28
|
14
|
13
|
23
| | |
|
Number of metastatic nodes
|
2.09 ± 4.16
|
2.94 ± 5.01
|
6.77 ± 9.63
|
11.88 ± 11.37
|
4.89 ± 9.70
|
9.167
|
0.000
|
|
Clinical stage
| | | | | |
50.721
|
0.000
|
|
I
|
33(27.7%)
|
15(28.8%)
|
1(4.5%)
|
0(0%)
|
10(21.7%)
| | |
|
IIA
|
38(31.9%)
|
11(21.2%)
|
10(45.5%)
|
4(25.0%)
|
13(28.3%)
| | |
|
IIB
|
39(32.8%)
|
21(40.4%)
|
4(18.2%)
|
4(25.0%)
|
16(34.8%)
| | |
|
IIIA
|
7(5.9%)
|
3(5.8%)
|
3(13.6%)
|
3(18.8%)
|
2(4.3%)
| | |
|
IIIB
|
1(0.8%)
|
2(3.8%)
|
2(9.1%)
|
1(6.3%)
|
1(2.2%)
| | |
|
IIIC
|
1(0.8%)
|
0(0%)
|
2(9.1%)
|
4(25%)
|
4(8.7%)
| | |
|
IV
|
0(0%)
|
0(0%)
|
0(0%)
|
0(0%)
|
0(0%)
| | |
|
P53 (%)
|
27.76 ± 30.19
|
32.65 ± 34.17
|
41.55 ± 30.32
|
30.19 ± 32.23
|
35.50 ± 35.33
|
1.141
|
0.338
|
|
Operation
| | | | | |
5.455
|
0.244
|
|
Mastectomy
|
102
|
47
|
21
|
16
|
43
| | |
|
Tumorectomy
|
17
|
5
|
1
|
0
|
3
| | |
|
Chemotherapy program
| | | | | |
49.253
|
0.002
|
|
Not performed
|
1(0.8%)
|
0(0%)
|
0(0%)
|
0(0%)
|
1(2.2%)
| | |
|
CMF
|
2(1.7%)
|
0(0%)
|
0(0%)
|
0(0%)
|
0(0%)
| | |
|
CAF or AC
|
42(35.3%)
|
17(32.7%)
|
2(9.1%)
|
0(0%)
|
11(23.9%)
| | |
|
CEF or EC
|
21(17.6%)
|
12(23.1%)
|
10(45.5%)
|
5(31.3%)
|
14(30.4%)
| | |
|
T or TC or TP
|
42(35.3%)
|
15(28.8%)
|
4(18.2%)
|
2(12.5%)
|
13(28.3%)
| | |
|
TAC or A-T
|
10(8.4%)
|
8(15.4%)
|
6(27.3%)
|
9(56.3%)
|
7(15.2%)
| | |
|
Radiotherapy
| | | | | |
6.682
|
0.154
|
|
Not performed
|
67
|
27
|
10
|
4
|
27
| | |
|
Performed
|
52
|
25
|
12
|
12
|
19
| | |
|
Endocrine therapy
| | | | | |
262.436
|
0.000
|
|
Not performed
|
0(0%)
|
0(0%)
|
0(0%)
|
16(100%)
|
46(100%)
| | |
|
TAM
|
75(63.0%)
|
32(61.5%)
|
12(54.5%)
|
0(0%)
|
0(0%)
| | |
|
LHRH
|
11(9.2%)
|
7(13.5%)
|
0(0%)
|
0(0%)
|
0(0%)
| | |
|
AI
|
33(27.7%)
|
13(25.0%)
|
10(45.5%)
|
0(0%)
|
0(0%)
| | |
|
Targeted therapy
| | | | | |
33.619
|
0.000
|
|
Not performed
|
119(100%)
|
52(100%)
|
20(90.9%)
|
13(81.3%)
|
46(100%)
| | |
|
Performed
|
0(0%)
|
0(0%)
|
2(9.1%)
|
3(18.8%)
|
0(0%)
| | |
|
Overall survival
|
99.2%
|
98.1%
|
86.4%
|
87.5%
|
91.3%
|
17.629
|
0.024
|
|
Event
|
1
|
1
|
3
|
2
|
4
| | |
|
Deaths
|
1
|
1
|
3
|
2
|
3
| | |
|
Lost to follow-up
|
0
|
0
|
0
|
0
|
1
| | |
|
Median survival time
|
54.0
|
48.0
|
36.0
|
29.4
|
35.2
|
31.845
|
0.000
|
|
Disease-free survival
|
98.3%
|
94.3%
|
72.7%
|
75.0%
|
82.6%
|
56.588
|
0.001
|
|
Event
|
2
|
3
|
6
|
4
|
7
| | |
|
Local recurrence
|
0
|
1
|
0
|
0
|
0
| | |
|
Contralateral breast cancer
|
1
|
1
|
2
|
0
|
0
| | |
|
Lung metastasis
|
0
|
0
|
0
|
1
|
1
| | |
|
Hepatic metastasis
|
0
|
0
|
2
|
1
|
2
| | |
|
Brain metastasis
|
0
|
0
|
0
|
1
|
2
| | |
|
Multi-organ
|
1
|
1
|
2
|
1
|
2
| | |
|
Lost to Follow-up
|
0
|
0
|
0
|
0
|
1
| | |
|
Disease-free survival
|
54.0
|
48.0
|
35.4
|
22.5
|
31.7
|
59.248
|
0.000
|
|
Follow-up time
| | | | | |
4.741
|
0.001
|
|
Median
|
23.0
|
25.5
|
30.5
|
17.0
|
20.0
| | |
|
Range
|
12-59
|
12-49
|
12-38
|
12-25
|
12-53
| | |
